GNPX GENPREX INC Business Restructuring 8-K Filing 2024 - Subsidiary Formation Genprex, Inc. plans to create a new subsidiary to focus on its diabetes gene therapy program, GPX-002, while retaining its oncology assets, with the separation expected by the end of 2024, pending financing and approvals.Get access to all SEC 8-K filings of the GENPREX INC